Conclusion: Our data suggest a possible role for GPR183-oxysterol interactions in driving aberrant B cell differentiation in (J)SLE and identify this pathway as potential therapeutic target in this disease. The gene discussed is GPR183; the disease is systemic lupus erythematosus.